ONCORENA

The treatment is based on research led by professor Börje Haraldsson at the University of Gothenburg, Sweden. The project was initially developed with support from Vinnova, Sweden's Innovation Agency, GU Ventures at the University of Gothenburg, and private business angels. Today, Oncorena is mainly financed by the investment companies HealthCap, Linc AB, Fåhraeus Startup and Growth AB, as well as the biopharma company AQILION AB... Oncorena AB is a Swedish pharmaceutical company founded in 2011, in Gothenburg, with the mission to develop a breakthrough treatment for metastatic renal cancer headquartered in Lund. Our objective is to confirm the powerful anti-tumor activity and other clinical benefits of orellanine in advanced kidney cancer patients.

Also known as: Oncorena AB

Primary location: Lund Sweden